Press Releases uniQure N.V.

Equities

QURE

NL0010696654

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
5.01 ^USD	-1.18%		+1.83%	-26.00%

May. 08	Mizuho Adjusts uniQure's Price Target to $6 From $7, Keeps Neutral Rating	MT
May. 07	UniQure N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

UniQure: Q1 Earnings Snapshot	May. 07	AQ
UniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress	May. 07	GL
UniQure Announces 2023 Financial Results and Highlights Recent Company Progress	Feb. 28	GL
UniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease	Dec. 19	GL
UniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease	Dec. 19	AQ
UniQure N : December 2023 Huntington's Disease Program Update AMT-130	Dec. 19	PU
UniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Dec. 08	GL
UniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Dec. 08	AQ
UniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry Disease	Nov. 29	GL
UniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry Disease	Nov. 29	AQ
UniQure: Q3 Earnings Snapshot	Nov. 07	AQ
UniQure Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress	Nov. 07	GL
UniQure Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress	Nov. 07	AQ
CSL and uniQure Win 2023 Prix Galien USA Award	23-10-30	AQ
CSL and uniQure Win 2023 Prix Galien USA Award	23-10-27	PR
Health Canada Authorizes CSL's HEMGENIX® (etranacogene dezaparvovec) as First Gene Therapy for Hemophilia B	23-10-26	AQ
UniQure Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting	23-10-24	GL
UniQure Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting	23-10-24	AQ
UniQure Announces Strategic Reorganization to Reduce Operating Expenses and Support Advancement of Multiple Clinical-Stage Programs	23-10-05	GL
UniQure Announces Strategic Reorganization to Reduce Operating Expenses and Support Advancement of Multiple Clinical-Stage Programs	23-10-05	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases uniQure N.V.

Equities

QURE

NL0010696654

Press Releases

Filters